Standford University has conducted research by analysing data from over 700,00 people across 46 countries on their day-to-day activity. This study uses smartphone data to track daily steps. This research is published in the journal Nature which highlights different countries and their activity levels.

In the year 2018, the World Health Organisation (WHO) also conducted similar research published in The Lancet, a medical journal which ranked Uganda as the most energetic country, with only 5.5 per cent of its population being inactive. While India ranked 117 among the 168 countries with 34 per cent of its population being inactive.

Let’s dig in to see who ranks where on the recent list

Indonesia

Measuring the average daily steps, Indonesia has topped the charts of being the most inactive country. The country also recorded the lowest average daily steps with just 3,513 average steps per day.

The study also highlights the need for better urban planning and public health initiatives which can help in more pedestrian activities. As per the studies, the current infrastructure is what discourages the Indonesians from walking and carrying on other physical activities to stay fit.

Saudi Arabia

This country has recorded an average of 3,807 steps per day. The report also states that the reason behind this low activity may be due to the hot climate. Other reasons are the cultural factors, as most people there prefer to stay indoors, and it leads to a sedentary lifestyle. The report also takes note of the different programmes by the government to promote a healthy lifestyle, including indoor exercise facilities.

Malaysia

The third on the list is Malaysia with average daily steps of 3,963. As per the report, the main factor behind a low daily average is motorisation. Cities like Kuala Lumpur and Penang also have high traffic, which may be the reason why people find walking less appealing.

The report here too has highlighted the government initiatives in promoting public health and healthy lifestyle.

Philippines

This country is at 4,008 steps per day. Almost every country has similar factors and needs better traffic management and urban infrastructure to promote a healthy lifestyle.

South Africa

Ranking fifth in the list is South Africa with 4,105 average steps a day. The report mentions the disparities of the diverse people and regions and attributes the urban areas as the cause of lower activity zones.

Egypt

On the list is Egypt with 4,315 average steps per day. The reason here is similar to Saudi Arabia, the hot climate is what plays an essential role in discouraging people from going out and walking. Traffic congestion too is the reason.

Brazil

Seventh on the list is Brazil with 4,289 steps. Here too, socio-economic disparities play a vital role in low physical activity. The report mentions that public health initiatives can improve the state of physical activity in the country.

India

Our country ranks eighth on the list with a daily average of 4,297 steps. Lifestyle changes are said to be the major factor in the love of physical activities among Indians. Metro cities like Delhi, Mumbai and Bengaluru, where people prefer motorised transport too, are the reason for the low activity rate.

Mexico

Ninth on the list with an average of 4,692 steps per day is Mexico. Here too, socio-economic factors play an essential role, along with traffic congestion and limited pedestrian infrastructure.

United States

The US is also on the list, number 10th with 4,774 average steps per day. This is a developed nation with a decent pedestrian infrastructure and yet the country ranks in the top 10 due to the increasingly sedentary lifestyle. Some cities are walkable, while others are not, this too is a leading factor for the US to feature on the list.

Health Risks

Walking is one of the most accessible and effective forms of exercise for maintaining heart health. Regular walking, maintaining an average of 10000 steps a day can improve cardiovascular function by strengthening the heart muscles, enhancing circulation, and reducing blood pressure.

It also helps with maintaining a healthy weight, It also aids in maintaining a healthy weight, which is essential for preventing heart disease. It can also keep the cholesterol levels in check.

Whereas a completely sedentary lifestyle can have detrimental effects on heart health. Physical inactivity is a significant risk factor for developing cardiovascular diseases.

Without regular exercise, the heart muscles weaken, leading to poor circulation and higher blood pressure. It also contributes to weight gain, and health issues such as hypertension, diabetes, and high cholesterol—all of which are risk factors for heart disease.

Amid the ongoing measles outbreak in the United States, the state of North Carolina has confirmed its first case in 2025. The North Carolina Department of Health and Human Services (NCDHHS) confirmed a case of measles in a child who was visiting Forsyth County and Guilford County.

How Did The Child Fall Sick?

The child became ill while traveling to North Carolina from a region where measles had already been reported. The news is confirmed as per the NCDHHS release.

The authorities are now also asking people who have visited the below mentioned location to review their immunization records or contact a healthcare provider to ensure that you are updated with the measles-mumps-rubella vaccine.

The Locations Are:

• PTI Airport in Greensboro
• Sleep Inn, 1406 Heartland Dr., Kernersville
• McDonalds, 14000 Heartland Dr., Kernersville
• Greensboro Science Center, 4301 Lawndale Dr., Greensboro
• Ice cream shop at Piedmont Triad Farmers Market, Greensboro
• Greensboro Aquatic Center Foyer, 1921 W. Gate City Blvd., Greensboro
• Greensboro Partee Shack, 3712 S. Holden Rd., Greensboro
• Lowes Foods, 240 Market View Dr., Kernersville

What Are The safety Guidelines?

The NCDHHS has also recommended that anyone unvaccinated and older than one year must get the measles vaccination.

However, when it comes to lab tests, the NCDHHS recommends that it is not necessary for people who were exposed, unless they develop symptoms of measles, including fever and rash. These symptoms can start from 7 to 21 days of getting infected. “Getting vaccinated against measles continues to be the most important step we can take to protect ourselves and our loved ones,” NCDHHS Secretary Dev Sangvai said. “It is important to check with your health care provider to ensure you are current with all your vaccines.”

What Is Measles?

As per the Centers for Disease Control and Prevention (CDC), measles is a highly contagious disease that comes with rashes and are especially prone to kids under the age of 5.

If one person gets it then 9 out of 10 people around the infected person may become infected.

Measles, also known as rubeola, is one of the most contagious infectious diseases, with at least a 90% secondary infection rate in susceptible domestic contacts. It can affect people of all ages, despite being considered primarily a childhood illness.

Measles is marked by prodromal fever, cough, coryza, conjunctivitis, and pathognomonic enanthem (ie, Koplik spots), followed by an erythematous maculopapular rash on the third to seventh day.

Who Is At Risk?

The World Health Organization (WHO), calls measles as one of the world's most contagious disease, which is spread by contact with infected nasal or throat secretions through coughing or sneezing, or breathing the air that was breathed by someone with measles. The virus remains active and contagious in the air or on infected surfaces for up to two hours.

WHO notes that any non-immune person (not vaccinated or vaccinated but did not develop immunity) can become infected. Unvaccinated young children and pregnant persons are at highest risk of severe measles complications.

A new clinical trial has uncovered the breakthrough promise of a new weight loss medication, MariTide, that can be taken only once monthly. Amgen developed the investigational drug, and it has demonstrated remarkable weight loss outcomes up to 20% in individuals with obesity. The Phase 2 trial results, which were released in The New England Journal of Medicine and presented at the American Diabetes Association's annual meeting 2025, may be a turning point in the treatment of obesity and Type 2 diabetes worldwide.

MariTide is a GLP-1 receptor agonist, a type of drug whose behavior is well-known to reduce weight and control Type 2 diabetes. It differentiates from current competitors like Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro and Zepbound, because it has a distinct molecular structure. MariTide contains a monoclonal antibody that means the drug can remain in the body longer. This capability makes the drug possible to give as a once-monthly injection, a major improvement over its weekly-injected counterparts.

Amgen's Phase 2 clinical trial consisted of almost 600 adults, divided into two groups: one with obesity alone and the other with obesity and Type 2 diabetes. Volunteers were assigned to take one of three dose levels of MariTide or a dummy shot. They took monthly injections for 52 weeks, and some in the obesity group started with a low dose that was increased incrementally.

The findings from the Phase 2 clinical trial of MariTide were nothing short of remarkable. Participants who had obesity but did not have diabetes experienced an average weight loss of up to 20% of their body weight after 52 weeks of treatment. Meanwhile, those who were managing both obesity and Type 2 diabetes saw an average weight loss of up to 17%. In sharp contrast, patients in the placebo groups showed only slight decreases in body weight, 2.6% for the group with obesity alone and only 1.4% for the group with obesity and diabetes. These findings highlight the great potential of MariTide as a very effective, once-a-month weight loss treatment.

These findings place MariTide on par with Wegovy and Zepbound in weight loss effects. Although Wegovy studies recorded a 15% decrease after 68 weeks and Zepbound delivered a 22.5% decrease after 72 weeks, MariTide's monthly regimen and similar effectiveness make it a strong contender.

Health Benefits of Using MariTide

MariTide is not only gaining recognition for its effectiveness at weight loss—it's also emerging as a full-range cardiometabolic therapy. Based on trial results, patients on MariTide experienced a dramatic decrease in A1c values, a key measure of long-term blood glucose control. For patients with diabetes, the medication reduced A1c by as much as 2.2 percentage points, outpacing expected decreases of 1.5 to 2.0 points with established GLP-1 therapies such as Ozempic and Mounjaro. But the advantages didn't end there. The research also observed significant reductions in blood pressure, cholesterol, and markers of inflammation, pointing to the potential of MariTide beyond the scale. These results indicate that the drug may provide an all-around solution to obesity as well as other chronic diseases such as cardiovascular disease and type 2 diabetes, making it an attractive option in the changing scenario of metabolic health treatments.

How MariTide Works?

Similar to other GLP-1 receptor agonists, MariTide has a similar action to glucagon-like peptide-1, a hormone that controls blood glucose and hunger. It increases the release of insulin, decreases the release of glucagon, and retards gastric emptying. MariTide differs from other drugs in that it contains a monoclonal antibody that keeps the drug in the body longer. Monthly dosing is made possible by this advance, and treatment compliance may be enhanced by less frequent injections.

Side Effects of 'MariTide' That People Need to Know

Similar to other GLP-1 drugs, side effects in the gastrointestinal tract were most frequently reported during the trial. These consisted of:

• Nausea
• Vomiting
• Diarrhea
• Abdominal discomfort

The side effect profile was comparable to other drugs in the same class according to the research team and largely tolerable overall. Large-scale Phase 3 trials will be important to best evaluate long-term safety and infrequent adverse events, though.

MariTide vs Wegovy, Mounjaro, and Others

If approved, MariTide would represent Amgen's foray into a weight loss market led by Novo Nordisk and Eli Lilly. Wegovy and Mounjaro have experienced explosive growth as a result of their robust efficacy results. Yet, MariTide's monthly dosing regimen and dual utility in diabetes care and weight loss may resonate with a vast patient population.

The comparisons between MariTide and existing GLP-1 drugs have not yet been conducted. Still, the early data suggests that Amgen’s candidate could stand toe-to-toe with the industry giants.

What’s Next for MariTide?

Amgen said it plans a Phase 3 clinical trial to further study MariTide for 72 weeks. If all goes well, the results of this research may lead to FDA approval and future distribution worldwide. Most analysts expect it will be at least a couple of years before MariTide is widely available, though.

With rates of obesity on the rise globally and related health issues costing billions each year, effective, affordable, and sustainable weight-loss solutions have never been more vital. MariTide's encouraging results provide a timely new alternative to an expanding stockpile of obesity-fighting weapons.

Global pharma giant Novo Nordisk launched its blockbuster weight loss drug Wegovy in India, a pivotal moment in the battle against increasing obesity levels in the nation. This follows closely on the heels of Eli Lilly's Mounjaro launch in India.

Wegovy, the semaglutide-based GLP-1 receptor agonist, will be available by the end of the month across major pharmacy chains in India. The once-weekly injectable prescription drug has already changed the landscape of obesity management in the United States and Europe.

"One out of every three patients attain 20% weight loss using the increased dose of Wegovy," stated Vikrant Shrotriya, Managing Director, Novo Nordisk India. The firm has completed late-stage trials involving 3,500 people in India, indicating encouraging results in sustained weight loss.

Wegovy will come in several dosages, ranging from Rs 4,336 for 0.25 mg to Rs 26,015 for the highest 2.4 mg dose. Its price is comparable to its rival Mounjaro, which was also launched in India last month in March.

Wegovy is timely given the increasing weight problem in India. A recent National Family Health Survey reveals that 24% of Indian women and 23% of Indian men aged between 15 and 49 years are overweight or obese—a notable increase from past years. India, with a population of over 1.4 billion and fast-emerging lifestyle diseases, is a huge market for weight-loss medications.

The medication has already proven to be successful across the world. Clinical trials have indicated that Wegovy consumers would lose around 15% of their body weight on average, especially when combined with a balanced diet and regular exercise. For comparison, Mounjaro (tirzepatide), being a dual GIP and GLP-1 agonist, experienced close to 23% of weight loss under the same circumstances.

Novo Nordisk's launch in India is at a time of corporate leadership transition, following the recent resignation of CEO Lars Fruergaard Jorgensen. The move is said by analysts to be intended to protect market share in a competitive environment rising from Lilly competition as well as Indian generic drugmakers who are gearing up to move into the field of obesity drugs when semaglutide's patent is about to end in 2026.

Although Wegovy brings new hope to millions of people with obesity, there are warnings with the medication. The drug has a boxed FDA warning about the potential for thyroid cancer, as suggested by studies on animals. Because of this, the drug is not approved for use in someone with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).

As India joins the global fight against obesity with cutting-edge therapies, India is all set to benefit from Novo Nordisk's Wegovy, which is ready to provide a new, science-driven solution for long-term weight management. The competition has already turned hot, and for Indian consumers, it could mean more options, improved results, and a new age of obesity treatment.